The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food
- 1 January 1988
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 34 (5), 481-488
- https://doi.org/10.1007/bf01046706
Abstract
Olsalazine sodium (5,5′-azodisalicylic acid (OLZ)) was given to eight healthy volunteers as a 10 mg i.v. bolus dose and as a 1 g oral dose with and without food. To five fasting participants single oral doses of 2 g and 4 g were given. Blood and urine were collected during three weeks after each dose and were assayed for OLZ, a conjugate identified as a sulphate of OLZ (OLZs), 5-aminosalicylic acid (5-ASA), and N-acetyl-5-aminosalicylic acid (ac-5-ASA). The study showed that: 1. OLZ had a very short elimination half-life, mean 56 min. 2. OLZ was absorbed from the intestinal tract to a very small extent, as seen from the low systemic availability and low urinary excretion, 2.3% and 0.31% respectively, for a 1 g dose taken fasting. 3. OLZ was present in the serum partly as a conjugate, which was identified as an O-sulphate. Following the i.v. dose the serum half-life of the O-sulphate was estimated to be 7 days. 4. Food intake did not influence the systemic availability of OLZ and ac-5-ASA. 5. There was no dose-dependent increase of OLZ absorption with single doses up to 2 g, but a 4-g dose showed a more than two-fold increase in the individual peak serum concentration and in the systemic availability of OLZ. However, there was no significant increase in the mean residence time (MRT) for OLZ or in the serum concentration of either 5-ASA or ac-5-ASA at a dose of 4 g.This publication has 26 references indexed in Scilit:
- Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditionsEuropean Journal of Clinical Pharmacology, 1992
- Transit of pharmaceutical dosage forms through the small intestine.Gut, 1986
- Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.Gut, 1982
- Rate limiting steps in metabolite kinetics: formation of 5-acetylaminosalicylate after administration of 5-aminosalicylateJournal of Pharmacy and Pharmacology, 1982
- TREATMENT OF ULCERATIVE COLITIS WITH HIGH-DOSE 5-AMINOSALICYLIC ACID ENEMASThe Lancet, 1981
- Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.Gut, 1980
- Capacity-limited Gut Wall Metabolism of 5-aminosalicylic acid, a Therapeutically Active Metabolite of Sulfasalazine, in RatsJournal of Pharmaceutical Sciences, 1979
- A new method for the determination of the binding capacity of testosterone-estradiol-binding-globulin in human plasmaJournal of Steroid Biochemistry, 1973
- Nephrotoxic Lesions from 5-Aminosalicylic AcidBMJ, 1972
- CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITISThe Lancet, 1965